In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Optimism About Alzheimer’s Disease: Gene Therapy, Digital Therapeutics And New Biomarkers

Executive Summary

Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.   

You may also be interested in...



Precision And Prevention Key To Future Of Alzheimer’s Treatment

While a so-called disease modifying treatment has entered the market for the first time, in the form of Biogen’s Aduhelm, Alzheimer’s disease is unlikely to be cured by one drug alone. In Vivo explores the array of approaches to AD drug development, drawing on interviews with industry leaders and pipeline data.

Microsoft’s Strategy In Health Care: Connection, Not Disruption

Through an ever-growing number of partnerships, grants and investments in the health care sector, Microsoft is taking a lead from behind approach to improve and expand interoperability, increase data security and analytics, and provide partners with tools, technology, and a platform for growth.

Is There An ‘October Surprise’ Coming For Drug Pricing?

US Congressional Democrats made Halloween the new deadline for President Biden’s Build Back Better Act, to be passed through the reconciliation process. Savings generated from prescription drug price cuts represent a key pot of money to offset the legislation’s other spending initiatives.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel